drugset / Trial / NCT03444844
Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer
Non-randomizedParallel-groupOpen-labelDiagnostic
Summary
Initial performance of Ga-68-P16-093 in prostate cancer patients including dosimetry and preliminary efficacy evaluation in BCR patients, and correlation of Ga-68-P16-093 uptake with tissue histopathology in intermediate to high risk primary prostate cancer patients.
Timeline
- Start
- 2018-05-10
- Primary completion
- 2020-10-27
- Completion
- 2022-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ga-68 P16-093 | Unknown | — | Intravenous |